MassMutual Private Wealth & Trust FSB Boosts Stake in Moderna, Inc. (NASDAQ:MRNA)

MassMutual Private Wealth & Trust FSB lifted its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 58.2% during the fourth quarter, Holdings Channel reports. The fund owned 1,057 shares of the company’s stock after purchasing an additional 389 shares during the quarter. MassMutual Private Wealth & Trust FSB’s holdings in Moderna were worth $44,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Arkadios Wealth Advisors increased its holdings in Moderna by 7.3% during the 4th quarter. Arkadios Wealth Advisors now owns 12,265 shares of the company’s stock worth $510,000 after purchasing an additional 836 shares during the last quarter. Avanza Fonder AB bought a new stake in shares of Moderna in the fourth quarter worth $1,393,000. Assenagon Asset Management S.A. raised its holdings in Moderna by 13.8% in the fourth quarter. Assenagon Asset Management S.A. now owns 14,978 shares of the company’s stock valued at $623,000 after acquiring an additional 1,819 shares in the last quarter. 180 Wealth Advisors LLC boosted its stake in Moderna by 3.2% during the 4th quarter. 180 Wealth Advisors LLC now owns 18,557 shares of the company’s stock valued at $772,000 after acquiring an additional 578 shares during the last quarter. Finally, Green Alpha Advisors LLC grew its holdings in Moderna by 54.9% during the 4th quarter. Green Alpha Advisors LLC now owns 16,900 shares of the company’s stock worth $703,000 after acquiring an additional 5,987 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Insider Transactions at Moderna

In related news, insider Shannon Thyme Klinger sold 1,418 shares of the business’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $42.79, for a total transaction of $60,676.22. Following the sale, the insider now owns 19,717 shares of the company’s stock, valued at $843,690.43. The trade was a 6.71 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last three months, insiders sold 2,664 shares of company stock valued at $115,210. Company insiders own 15.70% of the company’s stock.

Analyst Upgrades and Downgrades

MRNA has been the topic of several research analyst reports. Barclays reduced their price target on shares of Moderna from $125.00 to $111.00 and set an “overweight” rating on the stock in a research report on Friday, November 8th. Wolfe Research initiated coverage on Moderna in a research report on Friday, November 15th. They issued an “underperform” rating and a $40.00 target price for the company. Piper Sandler reissued an “overweight” rating and set a $69.00 price target (down from $115.00) on shares of Moderna in a research report on Monday, November 18th. Sanford C. Bernstein started coverage on shares of Moderna in a report on Thursday, October 17th. They issued a “market perform” rating and a $55.00 price objective for the company. Finally, Needham & Company LLC reissued a “hold” rating on shares of Moderna in a report on Friday, November 8th. Four research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $75.58.

Moderna Trading Down 2.3 %

Shares of MRNA stock opened at $41.41 on Friday. Moderna, Inc. has a 1 year low of $31.94 and a 1 year high of $170.47. The firm has a market capitalization of $15.94 billion, a PE ratio of -7.12 and a beta of 1.60. The stock has a fifty day moving average of $40.60 and a two-hundred day moving average of $64.04. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.20 and a current ratio of 4.39.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($1.89) by $1.92. The business had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The company’s quarterly revenue was up 3.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.39) earnings per share. As a group, research analysts expect that Moderna, Inc. will post -9.27 EPS for the current year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.